A diet rich in unsaturated fatty acids prevents progression toward heart failure in a rabbit model of pressure and volume overload by Ruijter, H.M. den et al.
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Background—During heart failure (HF), cardiac metabolic substrate preference changes from fatty acid (FA) toward
glucose oxidation. This change may cause progression toward heart failure. We hypothesize that a diet rich in FAs may
prevent this process, and that dietary 3-FAs have an added antiarrhythmic effect based on action potential (AP)
shortening in animals with HF.
Methods and Results—Rabbits were fed a diet containing 1.25% (w/w) high oleic sunflower oil (HF-9, N11), 1.25%
fish oil (HF-3, N11), or no supplement (HF-control, N8). Subsequently, HF was induced by volume and pressure
overload. After 4 months, HF-parameters were assessed, electrocardiograms were recorded, and blood and ventricular
tissue were collected. Myocytes were isolated for patch clamp or intracellular Ca2- recordings to study electrophysi-
ologic remodeling and arrhythmogenesis. Both the HF-9 and the HF-3 groups had larger myocardial FA oxidation
capacity than HF control. The HF-3 group had significantly lower mean ( SEM) relative heart and lung weight
(3.30.13 and 3.20.12 g kg1, respectively) than HF control (4.80.30 and 4.50.23), and shorter QTc intervals
(1672.6 versus 1826.4). The HF-9 also displayed a significantly reduced relative heart weight (3.60.26), but had
similar QTc (1794.3) compared with HF control. AP duration in the HF-3 group was20% shorter due to increased
Ito1 and IK1 and triggered activity, and Ca2-aftertransients were less than in the HF-9 group.
Conclusions—Dietary unsaturated FAs started prior to induction of HF prevent hypertrophy and HF. In addition, fish oil
FAs prevent HF-induced electrophysiologic remodeling and arrhythmias. (Circ Heart Fail. 2012;5:376-384.)
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In heart failure (HF), metabolic substrate preference shiftsfrom fatty acid oxidation (FAO) toward glucose oxida-
tion.1 It has been suggested that this change underlies the
progression toward HF.2 As a consequence, driving the
balance toward FAO is expected to prevent or slow down
the progression of HF and reduce the associated arrhythmias.
We hypothesize that this can be accomplished by a diet rich
in fatty acids (FAs).
Clinical Perspective on p 384
Heart failure is associated with a prolongation of ventric-
ular action potential (AP), which plays an important role in
the genesis of life-threatening ventricular tachyarrhythmias.3
Dietary 3- FAs cause a shortening of the AP duration (APD)
in healthy animals.4 Acute application of 3-FAs to isolated
myocytes from hearts of patients with HF led to APD
shortening and reduced incidence of triggered activity.5 It is
not known whether dietary 3-FAs exert the same action in
vivo.
The Diet and Reinfarction and GISSI trials (Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto mio-
cardico) addressed the potential beneficial effects of the
Mediterranean diet and showed that increased intake of fish
oil reduced cardiovascular death following a myocardial
infarction.6,7 This mainly was attributed to risk reductions in
sudden death in the GISSI Trial.7 Because ventricular
tachyarrhythmias often precede sudden death, the effect of
fish oil on arrhythmogenesis has been studied intensively in
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humans and animals.5,8–10 These studies show reductions in
severity and number of arrhythmias by fish oil. However, the
GISSI-HF trial showed that fish oil supplementation for 4
years in patients with severe HF resulted in a relatively small
absolute risk reduction in total mortality compared with the
original GISSI trial.11
The difference between the 2 GISSI trials7,11 is that in the
latter fish oil was provided to patients that had already developed
severe HF,11 whereas in the first GISSI trial, patients with a
recent myocardial infarction and with developing hypertrophy
were included.7 The different outcomes between trials may be
explained by a diet-induced retardation of the progression of HF
in the first but not the second GISSI trial.
We tested whether long term supplementation of the diet
with unsaturated (3- or 9-) FAs prior to the development
of HF by combined volume and pressure overload in rabbits
attenuates structural and functional remodeling and leads to
less hypertrophy and arrhythmias. Rabbits without dietary
supplements were used as control. We measured parameters
of HF, electrocardiograms, and markers of FAO, as well as
triggered arrhythmias and cardiac electrophysiological pa-
rameters 4 months after the induction of HF.
Methods
Design of the Study
The investigation was approved by the local ethical committee and
conformed to the Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85–23, revised 1996).
The design of the study is shown in Figure 1. Male New Zealand
White rabbits (2.5–3 kg) were allocated to 1 of 4 groups. Group 1
consisted of rabbits on a diet (150 g/d) without added FAs that
underwent volume and pressure overload (HF control; n8). Group
2 and 3 consisted of rabbits on a diet (150 g/d) supplemented with
either 1.25% (w/w) 9-sunflower oil (HF-9; n11) or 3-fish oil
(HF-3; n11) that underwent volume and pressure overload.
Group 4 consisted of rabbits on a diet (150 g/d) without added FAs
(control; n5).
Heart failure was induced by combined volume and pressure
overload as described before, typically inducing concentric hyper-
trophy as well as some left ventricular dilatation of the heart.12
Volume overload was induced by aortic valve rupture (100% pulse
pressure increase). Three weeks later, pressure overload was created
by a 50% suprarenal aortic stenosis. After 4 months, the rabbits
were anesthetized by a combination of ketamine (50 mg im) and
xylazine (10 mg im), blood was collected, and an ECG was recorded.
The rabbits were then heparinized (5000 IU) and killed by intrave-
nous injection of pentobarbital (240 mg). Body weight, heart weight,
and lung weight were measured, and the presence of ascites and
pericardial and thoracic fluid documented.10 Left ventricular tissue
was collected and stored at 80°C.
Diets
The diets (RDS, Wijk bij Duurstede, NL) contained 3.5% (w/w)
fat, mainly linoleic acid. The addition of 1.25% sunflower oil and
1.25% 3-fish oil increased mono-unsaturated FAs in the 9-diet
(C18:19), and eicosapentaenoic acid and docosahexaenoic acid
(EPA-C20:53 and DHA-C22:63) in the 3-diet (see online-only
Data Supplement Table I).
Analysis of Diet, Tissue, and Plasma
Lipids from the food and tissue were extracted according to Folch et
al.13 Phospholipids were isolated with Bond Elut Aminopropyl solid
phase extraction columns. Saponification and methylation of the
phospholipids with boron trifluoride (Pierce) was performed, and the
formed FA methyl esters were subjected to capillary gas chromatog-
raphy using a Chrompack column (Fused Silica, Chrompack), a
flame ionization detector, and H2 as carrier gas. FA methyl esters
were expressed as a fraction of the total amount. To determine the
plasma lipid profiles (total, low density lipoprotein [LDL], and high
density lipoprotein [HDL] cholesterol, and triglycerides), samples
were analyzed with spectrophotometry (enzymatic color test) using
commercial kits (Roche Diagnostics GmbH).
Cell Preparation
Midmyocardial myocytes were isolated by enzymatic dissociation
from the left ventricular free wall.14 Aliquots of cells were super-
fused (37°C) in a recording chamber on the stage of an inverted
microscope. Quiescent rod-shaped cross-striated cells with a smooth
surface were selected.
Electrophysiology
Electrocardiogram
QT segments were corrected for heart rate using linear regression
analysis obtained from 37 healthy control rabbits. Accordingly, the
QT intervals were normalized to an RR interval of 4 Hz using the
formula QTcQT–0.26*(RR–250).
Current-Clamp and Voltage-Clamp
See the online-only Data Supplement.
Ca2 Transients
Intracellular Ca2 (Ca2i) was measured in indo-1-am loaded
myocytes as described previously.12 Dual wavelength emission of
indo-1 was recorded ([405–440]/[505–540] nm, excitation at 340
nm), and free Ca2i was calculated.12
Gene Expression and Enzymatic
Activity Determination
Left ventricular samples were homogenized and total RNA was
isolated. An additional wash step of 70% ethanol increased the RNA
purity. Integrity of the RNA was checked by means of 260/280 ratio.
cDNA synthesis and quantitative polymerase chain reaction (qPCR)
assays were performed (for primers see online-only Data Supplement
Table II).15 Results were normalized to the geometric mean of 2
reference genes, that is, cyclophilin A and hypoxanthine guanine
phosphoribosyl transferase,16 using qBase software.17
Activity
Left ventricular tissue was homogenized in cold phosphate-buffered
saline followed by sonication on ice (twice 40J at 8W output).
Homogenates were centrifuged for 10 minutes at 1000 g. Carnitine
palmitoyltransferase 1 (CPT 1) activity was assessed by measuring
the [U-13C] palmitoylcarnitine from carnitine, and [U-13C]
palmitoyl-CoA on the tandem-mass spectrometer as previously
described.18 Incubations were performed in the presence and absence
of 0.2 mmol/L malonyl-CoA. The activity inhibited by malonyl-CoA
was considered to represent CPT 1.
Figure 1. Study outline.
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Proteomics
Cardiac tissue protein homogenates were prepared by grinding
frozen tissue from 5 HF control, 8 HF-9, and 10 HF-3 rabbits
in liquid nitrogen and homogenizing them in a lysis buffer
(7 mol/L Urea, 2 mol/L Thiourea, 2% CHAPS [3-[(3-
cholamidopropyl)dimethylammonio]-1-propane-sulfonic acid],
0.06% proteinase inhibitor cocktail [Roche]). Protein concentra-
tions were determined using the RC/DC [reducing agent compat-
ible, as well as detergent compatible] assay (BioRad), and 300 g
of protein were loaded per gel. BioRad IPG strips (pI 5– 8) were
used for the separation of proteins in the first dimension, and
SDS-PAGE was performed on 18x18 cm acrylamide gradient
(8%–16%) gels for the separation of proteins in the second
dimension. Flamingo (Biorad) fluorescent-stained gels were analyzed
using SameSpots (Nonlinear Dynamics). Spot density values were
exported from the SameSpots software into R 2.11.1 (R Foundation for
Statistical Computing) to perform statistical analysis as described below.
Spots were excised from the gel using a robotic spot cutter (BioRad),
trypsinized using a MassPrep Station (Micromass), and analyzed by
LC-ESI-MS/MS.19
Statistics
Data are meanSEM (n,N: number of cells, rabbits). Data were
statistically analyzed using 1- or 2-way ANOVA, on ranks (with
Kruskal-Wallis test) or repeated measures ANOVA if appropriate. In
repeated measures ANOVA, voltage steps were modeled as a
categorical factor and cells as the repeated factor, without interac-
tion. Post hoc testing for multiple comparisons was done with the
Holm-Sidak, Fisher LSD Method (with parametric ANOVA), or
Dunn test (with nonparametric ANOVA); P0.05 was considered
statistically significant).
Results
Fatty Acid Oxidation
Left ventricular activity of CPT 1, a rate-limiting enzyme
controlling mitochondrial import of FAs,20 was increased
significantly in the HF-9 and HF-3 groups compared with
HF control and control (Figure 2A). The cardiac mRNA level
of the -subunit of mitochondrial trifunctional protein
(HADHA), another FAO enzyme, was markedly decreased in
the HF control group compared with healthy control rabbits.
The 9- and 3-FA-enriched diets prevented the HF-
mediated decline in HADHA mRNA levels and even resulted
in significantly higher levels than in healthy control rabbits
(Figure 2B, P0.05 nonparametric ANOVA followed by
Dunn test). Glutamate dehydrogenase was not different ex-
cluding a general proliferation or enlargement of the mito-
chondria in these groups (data not shown).
Plasma and Tissue Content
The diets rich in 3-FAs resulted in a significant reduction of
plasma triglycerides compared with HF control and HF-9.
Triglyceride content in the 3-group was not different from
that of control rabbits (Table). There were no differences in
total cholesterol or LDL- or HDL-cholesterol between the
groups (data not shown).
In the HF-3 group, the 3-FA tissue-content comprised
15.50.5% of the total FAs extracted compared with 5.30.3%
in the HF control group and 4.70.2% in the HF-9 group. The
incorporation of 3-FAs was at the expense of 6-FAs and
9-FAs. There were no statistical differences in fat composition
in the heart between the HF-9 and the HF-control groups.
Supplemental Table III shows the myocardial phospholipid fatty
acid composition in the 4 groups (see online-only Data Supple-
ment). The percentage of 9-FA oleic acid in the myocardial
phospholipids is highest in the HF-9 group and in the control
group, and lowest in the HF-3 group.
Unsaturated Fatty Acids Prevent Cardiac
Hypertrophy During Developing Heart Failure
Weight gain was similar in the 4 groups (Table). The increase
of the aortic pulse pressure immediately after aortic valve
Figure 2. Fatty acid oxidation capacity.
A, Carnitine palmitoytransferase 1 activ-
ity in the ventricular myocardium of the 4
groups. Data are obtained from 5 to 6
animals per group. B, mRNA expression
of hydroxyacyl-CoA dehydrogenase/3-
ketoacyl-CoA thiolase/enoyl-CoA hydra-
tase (trifunctional protein),  subunit rela-
tive to control. Data are obtained from at
least 3 animals per group. C, Myocardial
mRNA levels of markers of hypertrophy,
pro-BNP. D, SERCa2a. All data are
obtained from at least 5 rabbits per
group and are relative to control.
*P0.05 versus HF control; †P0.05
versus control; ‡P0.05 versus HF-9
(1-way ANOVA).
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rupture was 1021.3, 1010.9, and 1000.7% for HF
control, HF-9, and HF-3, respectively (P0.05).
The HF control group had a significantly larger (relative)
heart and lung weight than the control rabbits. In addition, the
majority of the HF control rabbits had ascites and thoracic
and pericardial fluid (Table). Although the trigger for the
development of hypertrophy and HF was the same in all HF
groups, the animals that received diets rich in 9- and
3-FAs had a significantly reduced relative heart weight
compared with HF control (P0.05, ANOVA followed by
Fisher least significant difference (LSD) test; Table). In
addition, relative lung weight was lower in the HF-3 group
than HF control and did not differ from the control rabbits
(P0.05, ANOVA followed by Fisher LSD test; Table).
Supplemental Table IV shows the echocardiographic data
that reflect the heart weight data (see online-only Data
Supplement).
Pro-brain natriuretic peptide mRNA levels were measured
as an indicator of cardiac hypertrophy. Relative myocardial
mRNA levels of BNP were significantly lower in the HF-3,
HF- 9, and control group than HF control (P0.05, non-
parametric ANOVA followed by Dunn test; Figure 2C).
In the HF-3 and HF-9 group, SERCa2a mRNA levels
were significantly higher than HF control (P0.05, nonpara-
metric ANOVA followed by Dunn test; Figure 2D). In the
HF-3 group, SERCa2a mRNA levels were even higher than
in healthy control rabbits.
Fish Oil Fatty Acids Prevent
Electrophysiological Remodeling
In line with the increased heart weight in the HF control
group, the QRS duration was longer in HF control than
control (P0.05, ANOVA followed by Fisher LSD test).21
The HF-9 and HF-3 groups also had longer QRS durations
than the control rabbits, but this was significantly less than
the HF control group.
QTc was shorter in the HF-3 rabbits than HF-control and
HF-9, and similar to that of healthy controls (Table). The
heart rate did not differ between the groups. Figure 3A
displays typical APs recorded from isolated myocytes of the
4 groups at 1Hz pacing frequency. AP duration at 90%
repolarization (APD90) is prolonged significantly in the HF
control group compared with control at pacing frequencies
below 3 Hz (Figure 3B). Whereas APD90 in the HF-9 group
did not differ from HF-control, it was significantly shorter in
the HF-3 group than in the HF control group and not
different from control (Figure 3B). Similarly, the APD at
50% repolarization(APD50, 2 Hz) in HF control and HF-9
group was significantly longer (2028 and 19716 ms,
respectively) than control (1746 ms). The APD50 in the
HF-3 group (17210 ms) was similar to that of healthy
control rabbits. Both HF-3 and control were significantly
different from HF control and HF-9 (all P0.05, repeated
measures ANOVA). Cell capacitance data reflected heart
weight (see online-only Data Supplement Table V).
Figure 3C shows representative examples of Ca2 tran-
sients in 2Hz stimulated myocytes of all groups. Myocytes of
the HF-control group have increased diastolic [Ca2]i, de-
creased Ca2 transient amplitude, and slowed relaxation
compared with control and in HF-3 groups. In the HF-9
group, diastolic Ca2 was not different from the HF group,
and thus increased compared with control. In the same HF-9
group, however, Ca2 transient amplitude and relaxation time
were not different compared with control and HF-3 groups.
Data are summarized in Figure 3D. Diastolic Ca2 levels
were significantly lower in the HF-3 (987.9 nmol/L,
n19, P0.05 ANOVA followed by Holm-Sidak test) than
in HF control (1288.4 nmol/L, n26) and HF-9 (1206.8
Table. Characteristics (End of the Study)
Control (N5) HF-Control (N8) HF-9 (N11) HF-3 (N11)
Body weight (g) 3410 (80) 3430 (67) 3470 (44) 3590 (41)
Heart weight (g) 7.8 (0.37)* 16.7 (1.29) 12.7 (1.04)*† 11.7 (0.84)*†
Relative heart weight (g kg1) 2.3 (0.10)* 4.8 (0.3) 3.6 (0.26)*† 3.3 (0.13)*†
Lung weight (g) 11.6 (0.94) 15.5 (1.05) 13.0 (1.49) 11.6 (1.25)
Relative lung weight (g kg1) 3.4 (0.28)* 4.5 (0.23) 3.7 (0.39) 3.2 (0.12)*
Presence of ascites (%) 0 75 36 18
Presence of thoracic fluid (%) 0 88 18 9
Presence of pericardial fluid
(%)
0 63 64 36
Plasma lipids (N5) (N4) (N5) (N5)
Triglycerides (mmol/L) 0.55 (0.03)* 0.90 (0.06) 0.61 (0.03)* 0.45 (0.05)*‡
Total cholesterol (mmol/L) 0.51 (0.07) 0.49 (0.10) 0.43 (0.02) 0.43 (0.02)
ECG parameters (N5) (N8) (N11) (N11)
QRS duration (ms) 48 (1.1)* 61 (0.9) 55 (1.1)*† 55 (0.9)*†
Heart rate (Hz) 2.8 (0.18) 3.1 (0.15) 3.0 (0.16) 2.8 (0.11)
QTc (ms) 143 (3.0) 161 (10.4) 155 (5.8) 137 (2.5)*‡
Data are presented as mean (SEM). Statistical significance was tested wih ANOVA. *P0.05 vs HF-control; †P0.05 vs control;
‡P0.05 vs HF-9.
HF indicates heart failure.
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nmol/L, n32). Diastolic Ca2 levels were similar to those of
healthy control rabbits (945.7 nmol/L, n18).
Dietary Fish Oil Increases Ito1 and IK1 in
Heart Failure
To investigate the mechanism by which dietary fish oil
prevents AP prolongation, we studied the major ion currents
in the 4 groups (Figure 4A).
L-Type Ca2 Current
Figure 4B shows typical examples and current-voltage (I-V)
relationships of the L-type Ca2 current (ICa,L). Mean ICa,L
densities were similar in the control, HF control, and HF-3
group (Figure 4B). In the HF-9 group, ICa,L was signifi-
cantly larger at plateau potentials (5 to 5 mV) compared
with all other groups (P0.05 repeated measures ANOVA).
Voltage-dependency of ICa,L (in)activation did not differ
significantly between the 4 groups (data not shown).
Na-Ca2 Exchange Current
Figure 4C shows typical examples and I-V relationships of
the Na-Ca2 exchange current (INCX). There were no
differences in the reverse (outward) mode and in the forward
(inward) mode of the INCX between the 4 groups (Figure 4C).
K Currents
Figure 5A shows typical examples and I-V relationships of
the transient outward K current (Ito1). Mean Ito1 densities
were significantly larger in the HF-3 group than HF control
(P0.05 at 20 and 30 mV, repeated measures ANOVA;
Figure 5A). In the HF-9 group, Ito1 was larger at 30 mV
than HF control. Voltage dependency of Ito activation and
inactivation did not differ significantly between the 4 groups
(data not shown). Figure 5B shows typical examples and I-V
relationships of the inward rectifier K current (IK1). Mean
IK1 densities were similar in the HF control group compared
with control and were significantly larger at 110 and 100
mV in the HF-3 group than in the HF-9 group (P0.05
repeated measures ANOVA; Figure 5B). In addition, at100
and 90 mV, IK1 densities of the HF control and HF-9
group were significantly smaller than control. Figure 5C
shows typical examples and I-V relationships of the delayed
rectifier K current (IKr). Neither the IKr tail densities nor the
activation properties differed significantly between the 4
groups.
Fish Oil Inhibits Triggered Arrhythmias
Representative examples of transmembrane potentials in the
4 groups in the presence of 1 mol/L noradrenalin after rapid
pacing are shown in Figure 6A. In the HF control and the
HF-9 myocytes, the last stimulated AP (arrow) is followed
by delayed after depolarizations (DADs) and a triggered AP.
In the HF-3 myocyte, a DAD was present, but triggered APs
did not occur. In isolated myocyte of the control group no
arrhythmias occurred.
Triggered APs and DADs were abundantly present in the
HF control and in the HF-9 group compared with control
(both P0.05, nonparametric ANOVA followed by Dunn
test; Figure 6B). There was a significant reduction in both
triggered APs and DADs in the HF-3 group compared with
Figure 3. Fish oil prevents action potential (AP) prolongation. A, Representative APs (1 Hz pacing frequency). B, Averaged APD90 as a
function of pacing frequency. *P0.05 versus HF control; †P0.05 versus control; ‡P0.05 versus HF-9 (repeated measures
ANOVA). C, Representative examples of Ca2 transient in 2-Hz stimulated myocytes. D, Average data of diastolic Ca2, Ca2 tran-
sients amplitude, and 80% recovery time of the Ca2 transients in myocytes from the HF control (n26 cells), HF-9 (n32), HF- 3
(n19,) and control (n18) groups. *P0.05 versus HF control; †P0.05 versus control; ‡P0.05 versus HF-9 (1-way ANOVA).
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both HF control and HF-9. The incidence of triggered APs
was 17% and 14% in the HF control and HF-9 group,
respectively, and significantly less in the control (0%) and
HF-3 myocytes (7%).
Proteomics
A hypothesis free proteomic approach was followed to
identify potential protein expression changes that could un-
derlie the electrophysiological differences between the
Figure 4. A, Schematic representation of the action potential and its major ion currents. B, Top: 2-step protocol for L-type Ca2 cur-
rent (ICa,L) measurement. Middle: typical examples of ICa,L during voltage steps to 0 mV. Bottom: average current-voltage (I-V) relation-
ship of ICa,L. *P0.05 versus HF control; †P0.05 versus control; Pˆ0.05 versus HF-3 (repeated measures ANOVA). C, Top: the Na
-
Ca2 exchange current (INCX) was measured in Ca
2-buffered conditions as the Ni2-sensitive current during a descending voltage
ramp protocol. Middle: typical examples of INCX. Bottom: average I-V relationship of INCX.
Figure 5. A, Top: 2-step protocol for transient outward K current (Ito1) measurement. Middle: typical examples of Ito1 during voltage
steps to 40 mV. Bottom: average current-voltage (I-V) relationship of Ito1. B, Top: protocol for inward rectifier K
 current (IK1) measure-
ment. Middle: typical examples of IK1 during voltage steps to 110 mV. Bottom: average I-V relationship of IK1. *P0.05 versus HF
control; †P0.05 versus control; ‡P0.05 versus HF-9 (repeated measures ANOVA). C, Top: protocol for delayed rectifier K current
(IKr)measurement. Middle: typical examples of IKr during voltage steps to 10 mV. IKr was defined as the tail current on stepping back to
the holding potential. Bottom: average I-V relationship of IKr.
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HF-9 and HF-3 groups. In general, few significant differ-
ences were detected between HF-9, HF-3, and control
groups. The main changes were represented by an increase of
levels of cardiac albumin and very long-chain specific acyl-
CoA dehydrogenase by HF-9, and an increase of levels of
nicotinamide adenine dinucleotide dehydrogenase flavopro-
tein 1 and adenosine triphosphate synthase subunit by HF-9
and HF-3, compared with control (see online-only Data
Supplement Figure I and Table VI).
Discussion
In this study we showed that long-term dietary supplementa-
tion with unsaturated FAs started before the induction of HF
attenuated the development of cardiac hypertrophy and pre-
vented progression toward HF. Supplementation with fish oil
but not sunflower oil also prevented electric remodeling
associated with HF, leading to reduced susceptibility of
arrhythmias. The data support the notion that FA-enriched
diets maintain myocardial FAO capacity and are associated
with reduced progression of HF and arrhythmogenesis.
The reduced hypertrophy in the HF-9 group in itself
makes the heart less vulnerable for re-entrant arrhythmias.
However, the relatively long action potential, and increased
diastolic Ca2 and ICa,L, resulted in a similar number of
arrhythmogenic triggers as in the HF control group. Thus,
3-FAs should be preferred over 9-FAs because these
reduce both hypertrophy and triggered arrhythmias.
Unsaturated Fatty Acids Maintain Myocardial
Fatty Acid Oxidation Capacity
Heart failure leads to a reduction in cardiac FAO capacity.1
The increased CPT 1 activity and mRNA levels of the
mitochondrial trifunctional protein in the HF-3 and HF-9
groups indicate that increased FA intake may counteract this.
The hypothesis that FAs maintain myocardial FAO should be
evaluated further by measuring the change in myocardial
metabolism. Expression of both genes as well as many other
genes involved in FAO are regulated by peroxisome
proliferator-activated receptor, a transcription factor activated
by FAs (including 3- and 9-FAs).22 Thus, our data confirm
that unsaturated (fish oil) FAs suppress cardiomyocyte hy-
pertrophy in vitro and in vivo, and we speculate that this was
affected by activating proliferator-activated receptors.22
The cardioprotective mechanisms of fish oils are diverse,
and include antiarrhythmic, antiatherosclerotic, and anti-
inflammatory effects.23,24 In addition, 3-FAs incorporate in
the mitochondrial membranes of cardiac myocytes and
change FAO and mitochondrial respiration.25
Omega-3 and Omega-9 Fatty Acids Prevent
Cardiac Hypertrophy
We found that both dietary 3- and 9-FAs prevented cardiac
hypertrophy following combined volume and pressure overload.
Epidemiological studies show that increased intake of 3-FAs is
associated with reduced incidence of HF.26 Similarly, fish oil
diets in rats with pressure overload also prevented hypertro-
phy.27 Although there is limited experimental and clinical
evidence of the role of high fat diets in the pathogenesis of HF,
both animal studies and human studies show that high unsatu-
rated fat diets are not harmful for the heart and may even
improve biomarkers of cardiovascular disease.28
Omega-3 Fatty Acids Are Increased in
Cardiac Tissue
In the HF-3 group, this diet increased myocardial levels of
3-FAs by 10% at the expense of 6-FAs. In patients,
cardiac 3-FAs may increase up to 6% after fish oil
supplementation for 1 month.29 The similarity between our
data and the levels obtained in man suggests that the effects
observed in this study are relevant in human HF.
Note that the vaccenic acid (18:1n7) percentage is low, but
highest in the HF-3 group, suggesting that this trans FA did
not have any detrimental effect in our study, as suggested
recently.30
Unsaturated Fatty Acids Lower Triglycerides
During Developing Heart Failure
Our data show that the HF-3 and HF-9 groups both had
lower plasma triglycerides levels than the HF control group.
Omega-3 FAs appear to be superior in lowering plasma
triglycerides, as these were lower in the HF-3 group than in
the HF-9 group. Also in humans, the Mediterranean diet,
rich in monounsaturated fatty acids primarily from olives and
olive oil, and fish oils markedly decreased triglyceride
levels.31 Therefore, monounsaturated fatty acids not only
have antihypertrophic effects, but also have favorable meta-
bolic effects.
Figure 6. Fish oil prevents triggered activity. A, Representative
examples of the tracing periods. Arrows indicate last paced
action potential (AP). B, Data summary of the number of trig-
gered APs and delayed after depolarizations. *P0.05 versus
HF control and ‡P0.05 versus HF-9 (1-way ANOVA).
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Dietary Fish Oil But Not Sunflower Oil Prevents
Electric Remodeling in Heart Failure
In addition to a slowing effect on the progression of HF, the
fish oil diet resulted in a reduced QTc interval on the surface
ECG. This observation was supported in isolated myocytes of
the HF-3 group that displayed shorter APs. In all cardio-
myopathy models, Ito1 density is reduced.32 This was con-
firmed in our study in which we observed a 50% decrease
in Ito in the HF control group. The HF-3 and the HF-9
group did not display remodeling of Ito, which explains the
shorter AP in the HF-3 group. In the HF-9 group,
however, ICa,L was larger than in the other groups, explaining
the longer APs and the higher diastolic Ca2 levels compared
with the HF-3 group. In addition, increased Ca2 influx
through L-type Ca2 channels by necessity leads, under
steady state conditions, to increased efflux of Ca2 through
the Na-Ca2 exchanger and to increased depolarizing INCX
and AP prolongation. Because calcium handling was im-
paired in the HF-9 group despite the normalization of
SERCA2a mRNA, we cannot exclude that sarco/endoplas-
matic reticulum calcium ATPase function was compromised
nevertheless.
Fish oil has disparate effects on ion currents, and both an
increase and decrease in K currents have been de-
scribed.4,23,33 This appeared to depend on whether the FAs
were applied to the cells or incorporated in the membranes.23
Our study supports the idea that the effect of fish oil on
cardiac arrhythmias not only depends on the mode of appli-
cation, but also on the underlying cardiac pathology.
We followed a proteomics approach to identify potential
protein expression changes between the HF-9, HF-3, and
control groups. This failed to show major significant differ-
ences between groups, apart from an indication that oxidation
of very long chain FAs and oxidative phosphorylation may be
increased in HF-9, and to a lesser extent HF-3. Therefore,
the observed electrophysiological differences between the
HF-9 and HF-3 groups cannot be explained by regulation
of visualized proteins in the 2D gel, albeit that our approach
may not have been sufficiently sensitive to detect regulation
of pore forming and accessory subunits for each individual
ion channel that may have been affected by the dietary
interventions.
Potential Significance and Limitations
Dietary fish oil supplements are recommended for patients
after a myocardial infarction, as their cardioprotective effi-
cacy has been demonstrated in various clinical trials on the
Mediterranean diet.6,7,34 The result of the recent GISSI-HF,11
however, showed a modest protection against cardiovascular
death and hospitalization in patients with established HF.
We studied the effect of fish oil during the development of
HF without interference of medical therapies. In this setting,
fish oil supplementation prevented both structural and electric
remodeling associated with HF. This may explain why fish
oil supplementation causes a larger reduction in sudden death
in patients at risk for HF (after acute myocardial infarction)7
than in patients with established HF,11 even in the presence of
optimal medical therapy. Indeed, increased fish oil consump-
tion is reported to be associated with a reduced incidence of
HF.26,35 We would argue that the traditional diet-heart hy-
pothesis may need to be adjusted after confirmation of our
findings in man. The molecular mechanisms underlying these
effects remain uncertain, although our data suggest that an
increased capacity for myocardial FAO plays a role, as well
as the alteration of ion channel kinetics.
We were unable to specify the phospholipid content of the
sarcolemma in the 4 groups, and were limited by the paucity
of suitable antibodies for validation of protein changes.
Conclusion
Dietary unsaturated FAs supplementation initiated before the
development of HF reduces hypertrophy. In addition, fish oil
FAs prevent HF-induced electric remodeling and triggered
arrhythmias. Our study may explain why fish oil FAs are
powerful antiarrhythmic drugs during the development of HF.
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CLINICAL PERSPECTIVE
During heart failure, the cardiac metabolic substrate preference changes from fatty acid (FA) toward glucose. This change
may contribute to progression of disease. We addressed whether a diet rich in unsaturated fatty acids limits progression
toward HF. We fed rabbits with a diet rich in sunflower oil, fish oil, or control feed, and HF was induced by volume and
pressure overload. Both the FA-supplemented groups had increased myocardial FA oxidation. The sunflower oil group had
lower relative heart weight and had similar QTc interval as the HF control group. The fish oil group also displayed lower
heart weight, but had shorter QTc intervals on the ECG. The shorter QTc was explained by action potential shortening in
fish oil-fed animals and was caused by increased Ito1 and IK1, and resulted in reduced triggered arrhythmias in the fish oil
group. Thus, dietary supplementation with unsaturated fatty acids prevents hypertrophy and HF, and fish oil supplemen-
tation additionally prevents HF-induced electric remodeling. These data may contribute to understanding the potential
cardioprotective effects of Mediterranean diets in this setting. In addition, our data may shed light on why fish oil
supplementation is beneficial in patients with a recent myocardial infarction, but not in patients with established HF.
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